Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Collection of Blood and Bone Marrow From Patients With Aplastic Anemia for Analysis of Adhesion Molecules, Chemokines and Their Receptors

This study has been withdrawn prior to enrollment.
(No eligible patient was enrolled.)
Sponsor:
Information provided by (Responsible Party):
Ming Hou, Shandong University
ClinicalTrials.gov Identifier:
NCT01680055
First received: September 3, 2012
Last updated: April 18, 2016
Last verified: September 2012
  Purpose
This study is designed to collect bone marrow and/or peripheral blood cells and plasma, for the analysis of adhesion molecules, chemokines and their receptors from newly-diagnosed aplastic anemia patients, and patients treated with antithymocyte globulin plus cyclosporine

Condition
Aplastic Anemia
Healthy

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Shandong University:

Primary Outcome Measures:
  • hematologic response [ Time Frame: 6 months following antithymocyte globulin plus cyclosporine treatment ] [ Designated as safety issue: No ]
    hematologic response at 6 months following antithymocyte globulin plus cyclosporine treatment, defined as no longer meeting the criteria for severe aplastic anemia


Enrollment: 0
Study Start Date: February 2009
Estimated Study Completion Date: November 2012
Groups/Cohorts
AA-ATG
Acquired Aplastic Anemia Patients Treated with Antithymocyte Globulin plus Cyclosporine

  Eligibility

Ages Eligible for Study:   16 Years to 70 Years   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients With Aplastic Anemia
Criteria

Inclusion Criteria:

  • patients who fulfilled entry criteria of acquired aplastic anemia age range 16-70 years

Exclusion Criteria:

  • Patients complicated with diabetes, tumor, pregnancy, active infection, or connective tissue diseases, such as systemic lupus erythematosus.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01680055

Locations
China, Shandong
Qilu Hospital, Shandong University
Jinan, Shandong, China, 250012
Sponsors and Collaborators
Shandong University
  More Information

Responsible Party: Ming Hou, Director, Shandong University
ClinicalTrials.gov Identifier: NCT01680055     History of Changes
Other Study ID Numbers: Aplastic Anemia 1 
Study First Received: September 3, 2012
Last Updated: April 18, 2016
Health Authority: China: National Natural Science Foundation

Additional relevant MeSH terms:
Anemia
Anemia, Aplastic
Hematologic Diseases
Bone Marrow Diseases

ClinicalTrials.gov processed this record on September 23, 2016